中国药物经济学2025，Vol.20Issue(10)：22-27,33,7.DOI:10.12010/j.issn.1673-5846.2025.10.004
AP联合PD-1/PD-L1抑制剂治疗非小细胞肺癌的药物经济学评价
Pharmacoeconomic Evaluation of AP Combined with PD-1/PD-L1 Inhibitors in the Treatment of Non-small Cell Lung Cancer
摘要
Abstract
Objective To evaluate the economic viability of pemetrexed+cisplatin or carboplatin(hereinafter referred to as AP)combined with programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1)inhibitors in the treatment of patients with stage Ⅳ non-driver gene non-squamous cell non-small cell lung cancer(NSCLC).Methods The decision tree model was constructed through Treeage Pro 2011 software,with QALYs as the utility index,to simulate the cost input and benefit of 24 cycles of treatment with AP combined with PD-1/PD-L1 inhibitors in patients with stage Ⅳ non-driver gene non-squamous cell carcinoma NSCLC.The incremental cost-effectiveness ratio(ICER)of the AP combined with PD-1/PD-L1 inhibitor regimen and the AP regimen was compared,and the robustness of the model was verified through univariate sensitivity analysis and context analysis.Results Compared with the control group,when the will-to-pay(WTP)was 162 516 yuan,pembrolizumab,camrelizumab,sintilimab,and suglimab were acceptable treatment options compared with the AP regimen.Compared with the AP regimen,tislelizumab and atezolizumab are completely worthwhile advantageous regimens.The results of the single-factor sensitivity analysis indicated that the basic analysis results are relatively robust.The results of the scenario analysis show that the increase in drug costs and the adjustment of the medical insurance reimbursement ratio have little impact on ICER,and the basic analysis results are robust.An economic analysis of the increase in adverse reaction management costs and inspection and examination costs reveals that pembrolizumab,camrelizumab,sintilimab,tislelizumab,atezolizumab,and suglizumab are not economically viable.Conclusion For patients with stage Ⅳ non-driver gene non-squamous cell carcinoma NSCLC,the AP combined with PD-1/PD-L1 inhibitor regimen is more economical compared to the AP chemotherapy regimen under the centralized procurement policy of Guizhou Province.关键词
非小细胞肺癌/免疫检查点抑制剂/成本-效果分析/药物经济学Key words
Non-small-cell lung cancer/Immune checkpoint inhibitors/Cost-effectiveness analysis/Pharmacoeconomics分类
医药卫生引用本文复制引用
于佳,李玲,杨秋洁,张石宇,李广松..AP联合PD-1/PD-L1抑制剂治疗非小细胞肺癌的药物经济学评价[J].中国药物经济学,2025,20(10):22-27,33,7.基金项目
贵州中医药大学研究生教育创新计划教学改革项目(YCXJG202200) （YCXJG202200）
2024年度贵州省卫生健康委科学技术基金项目(gzwkj2024-522) （gzwkj2024-522）
